Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.57 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984644 | 0.94 | SLC5A2 (0.77) | SLC5A2 | |
| SCHEMBL9984149 | 0.90 | SLC5A2 (0.83) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL9985131 | 0.89 | SLC5A2 (0.82) | SLC5A2 | |
| SCHEMBL9984688 | 0.89 | SLC5A2 (0.77) | SLC5A2 | |
| SCHEMBL9986233 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL14841703 | 0.88 | SLC5A2 (0.80) | SLC5A2ABCB11ADORA3SLC5A1SLC6A4 | |
| SCHEMBL14841803 | 0.88 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL9984334 | 0.88 | SLC5A2 (0.76) | SLC5A2 | |
| SCHEMBL9984578 | 0.86 | SLC5A2 (1.00) | SLC5A2 | |
| SCHEMBL12069297 | 0.84 | SLC5A2 (0.70) | SLC5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | claimed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | claimed |
| WO-2011159067-A2 | THIAZOLE DERIVATIVES AS SGLT2 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2011-12-22 | — | — | WO | claimed |
| US-8586550-B2 | Thiazole derivatives as SGLT2 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2013-11-19 | — | — | US | disclosed |
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | GREEN CROSS CORPORATION (KR) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090298-A1 | Thiazole Derivatives as SGLT2 Inhibitors and Pharmaceutical Composition Comprising Same | SLC5A2, SLC5A1, SLC10A2 | SLC5A2 1/4885ABCB11 252/4885ADORA3 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.